• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Compugen expands to California to develop mAb drug candidates

Compugen expands to California to develop mAb drug candidates

April 2, 2012
CenterWatch Staff

Compugen Inc., a Canadian therapeutic product discovery company, has established new operations in South San Francisco, Calif., for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

The expansion follows the Compugen’s December 2011 announcement of its intention to significantly broaden and accelerate its mAb activities. At that time, and in partial support of its mAb operations expansion, the company also announced an $8 million research funding agreement signed with Baize Investments, an Israeli private corporation that invests in innovative medical technologies.

Compugen Inc. hopes to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company (Compugen Ltd. based Israel) into promising mAb drug candidates for licensing and partnering. The new operations will be lead by Mary Haak-Frendscho, Ph.D., as executive chairperson and John J. Hunter, Ph.D., as vice president of antibody R&D and site head.

The new operations will be located in recently secured purpose-built facilities with relevant laboratory equipment. By locating its mAb operation in the birthplace of biotech, Compugen Inc. hopes to gain access to some of the best biologics talent in the industry and supportive infrastructure. Furthermore, with its new capabilities, the company anticipates it will significantly increase the number of mAb product candidates developed against novel Compugen-discovered targets by performing key activities more effectively and efficiently in-house compared with solely using third parties as previously intended.

Dr. Anat Cohen-Dayag, president and CEO of Compugen Ltd., said, "We are at a pivotal moment where Compugen's unique monoclonal antibody targets discovery platform is delivering high quality, novel mAb targets that enable the development of new drug candidates to address unmet medical needs. We enthusiastically look forward to leveraging the commercial potential of these pioneering and industry leading predictive discovery capabilities by licensing out — at significantly greater values — the differentiated mAb product candidates against these novel targets, rather than the targets.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing